Global Biobanking Market

Biobanking Market Size, Share, Growth Analysis, By Type(Population-based Biobanks, Disease-based Biobanks), By Sample(Blood Products, Cell Lines), By Application(Drug Discovery, Genomic Research) - Industry Forecast 2024-2031

Report ID: SQMIG35H2200 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 98 | Figures: 76

Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Analyst Support
$5,300
BUY NOW GET FREE SAMPLE

FAQs

Biobanking Market size was valued at USD 69.5 billion in 2022 and is poised to grow from USD 72 billion in 2023 to USD 95.5 billion by 2031, growing at a CAGR of 6.8% in the forecast period (2024-2031).

The competitive environment of the Biobanking market is dynamic and characterized by the presence of several key players engaging in strategic initiatives to solidify their market position. Established companies often focus on expanding their service offerings, investing in advanced technologies, and forming partnerships with research institutions and pharmaceutical companies. Additionally, mergers and acquisitions play a role in enhancing capabilities and extending geographic reach. The market's dynamism is further fueled by the entry of new players, particularly in emerging regions, contributing to increased competition. 'AMS Biotechnology (Europe) Ltd.', 'ASKION GmbH', 'Avantor, Inc.', 'Azenta, Inc. (Azenta)', 'Bay Biosciences LLC', 'BioIVT & Elevating Science', 'Boca Biolistics', 'CTI Biotech', 'Cureline Inc.', 'Firalis SA', 'Geneticist Inc.', 'Hamilton Bonaduz AG', 'Isenet Biobanking', 'Merck & Co., Inc.', 'ProteoGenex Inc.', 'Qiagen NV', 'Stemcell Holdings, Inc.', 'STEMCELL Technologies Inc.', 'Thermo Fisher Scientific Inc.', 'US Biolab Corp. Inc.'

The increasing biomedical research activities, particularly in genomics and personalized medicine, play a pivotal role in driving the demand for biobanking services. The rising prevalence of chronic diseases and the need for large-scale sample collections for clinical trials further contribute to the market's expansion. Additionally, the growing awareness of the potential of biobanks to advance scientific understanding, drug discovery, and disease research fuels the adoption of biobanking services globally. With the continuous evolution of precision medicine and the increasing importance of biomarker discovery, the biobanking market is expected to witness continued growth, driven by these fundamental drivers.

The increasing adoption of advanced technologies, such as automated sample storage systems and blockchain, to enhance the efficiency and security of biobanking operations. Additionally, there is a growing emphasis on expanding the diversity of stored samples to encompass various demographic groups, promoting more inclusive and representative research outcomes. The integration of artificial intelligence (AI) and machine learning for data analysis and interpretation is another key trend, facilitating more in-depth insights from stored biological samples.

North America is poised to dominate the biobanking marketplace. This dominance is attributed to the presence of superior healthcare infrastructure, enormous investments in studies and development, and an excessive occurrence of continual diseases. Moreover, the place has advantages from robust collaborations among instructional institutions, pharmaceutical companies, and studies organizations, fostering an surroundings conducive to biobanking activities.

Related Reports

Europe Dry Eye Syndrome Market
Buy Now GET FREE SAMPLE
Primary Cell Culture Market
Buy Now GET FREE SAMPLE
Automated Cell Culture Market
Buy Now GET FREE SAMPLE
Stem Cell Therapy Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Biobanking Market

Product ID: SQMIG35H2200

$5,300
BUY NOW GET FREE SAMPLE